Results 161 to 170 of about 1,177,456 (242)

Old disease, new twist

Journal of Hospital Medicine, Volume 21, Issue 11, Page 1305-1309, November 2026.
Abstract An 81‐year‐old man with a history of high‐grade urothelial carcinoma of the bladder and ureter on treatment with atezolizumab and tiragolumab presented to the emergency department with 5 months of malaise, generalized weakness, and fatigue and 2 weeks of subjective fevers. One month prior to presentation, he received an empiric 9‐day course of
Hadi Roudsari, Gurpreet Dhaliwal, Anand D. Jagannath, Alan H. Baik, Sam Brondfield   +4 more
wiley   +1 more source

Can the Prognostic Nutritional Index Be a Predictor of Acute Exacerbation of Idiopathic Pulmonary Fibrosis? [PDF]

Biomedicines
Çolak M, Çoban H.
europepmc   +1 more source

Triggering Receptor Expressed on Myeloid Cells‐2 Regulates Innate Lymphoid Cell Levels in Bleomycin‐Induced Pulmonary Fibrosis

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 11, November 2026.
ABSTRACT Idiopathic pulmonary fibrosis, a pathological change causing poor outcomes, is not reversible despite current antifibrotic therapy. Emerging evidence suggests that innate lymphoid cells (ILCs) mediate lung inflammation and fibrosis after stimulation by endogenous factors.
Hsiao‐Chin Shen, Nien‐Jung Chen, Chuan‐Yen Sun, Wen‐Kuang Yu, Vincent Yi‐Fong Su, Wan‐Ling Yang, Wei‐Chih Chen, Kuang‐Yao Yang   +7 more
wiley   +1 more source

Hepcidin as a Biomarker of Response to Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis. [PDF]

J Clin Med
Yilmaz Gunes G, Çoban H, Erel F, Akış Yılmaz M, Sarioglu N, Colak M, Yumrukuz Senel M.   +6 more
europepmc   +1 more source

Correction to “DLD‐HLNP/P@IR780 for efficient lung‐parenchyma accumulation to treat idiopathic pulmonary fibrosis”

VIEW, EarlyView.
wiley   +1 more source

Andrographolide Modulates Fibrogenic and Oxidative Stress Responses in Human Lung Fibroblasts

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 11, November 2026.
ABSTRACT Pulmonary fibrosis is a progressive lung disorder characterized by fibroblast activation and excessive extracellular matrix deposition. Andrographolide (ANDRO) has been reported to attenuate pulmonary fibrosis, but the underlying molecular mechanisms remain incompletely understood.
Yu‐Hsin Tseng, Yen‐Hsien Wu, Yi‐Ching Liu, I‐Chen Chen, Chung‐Yu Yeh, Shang‐En Huang, Ren‐Long Jan, Jwu‐Lai Yeh, Jong‐Hau Hsu   +8 more
wiley   +1 more source

Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis. [PDF]

Am J Respir Crit Care Med
Kim JS, Loe A, Ma SF, Ranjan P, Lipinski JH, Mikhail SG, Gurczynski SJ, Zhou X, Huffnagle GB, Downward JE, Metcalf JD, Falkowski N, Stringer KA, Dickson RP, Huang Y, Moore BB, Martinez FJ, Murray S, Noth I, O'Dwyer DN.   +19 more
europepmc   +1 more source

Inhaled Nanomedicines for Lung Diseases and Injuries: Pharmacological Advances and Clinical Translation

MedComm, Volume 7, Issue 11, November 2026.
Graphical overview of bioinspired regenerative platforms designed to remodel the diseased lung microenvironment. These systems integrate gene addition, siRNA‐mediated transcript silencing, CRISPR‐based modulation, and base editing approaches to promote alveolar repair, AT2‐to‐AT1 regeneration, resolution of inflammation, and restoration of vascular ...
Kajal Kamra, Sonal Gaur, Jaswinder Singh
wiley   +1 more source

Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry. [PDF]

Intern Med J
Chee M, Khor YH, Jackson D, Cooper W, D'Costa J, de Boer S, Edwards A, Ellis S, Gabbay E, Gallagher H, Glaspole I, Goh N, Grainge C, Hopkins P, Keir G, Kwan B, Mackintosh J, Moodley Y, Moore I, Navaratnam V, Ong C, Reynolds P, Royals K, Teoh A, Troy L, Veitch E, Wilsher M, Wrobel J, Zappala C, Corte T, Thien F, AILDR Steering Committee.   +31 more
europepmc   +1 more source

The PIEZO1/CISD1/IP3R Mechanotransduction Axis Drives Macrophage Mitochondrial Dysfunction and Inflammatory Activation in Pulmonary Fibrosis

MedComm, Volume 7, Issue 11, November 2026.
In the pulmonary fibrotic microenvironment, mechanical signals activate PIEZO1 to mediate Ca2+ entry into macrophages. Increased CISD1/IP3R activity promotes Ca2+ transfer from the endoplasmic reticulum to mitochondria, leading to mitochondrial Ca2+ overload and opening of the mitochondrial permeability transition pore (MPTP). Consequently, macrophages
Yungeng Wei, Chao Xie, Xiangsheng Yang, Xiao Xiao Tang   +3 more
wiley   +1 more source